NovaBay Pharmaceuticals Company Profile (NYSE:NBY)

About NovaBay Pharmaceuticals (NYSE:NBY)

NovaBay Pharmaceuticals logoNovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NYSE:NBY
  • CUSIP: N/A
  • Web: novabay.com/
Capitalization:
  • Market Cap: $70.42 million
  • Outstanding Shares: 15,309,000
Average Prices:
  • 50 Day Moving Avg: $4.46
  • 200 Day Moving Avg: $3.72
  • 52 Week Range: $2.25 - $5.09
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -65.71
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $15.34 million
  • Price / Sales: 4.59
  • Book Value: $0.21 per share
  • Price / Book: 21.90
Profitability:
  • EBIDTA: ($9,470,000.00)
  • Net Margins: -42.16%
  • Return on Equity: -184.30%
  • Return on Assets: -56.33%
Misc:
  • Average Volume: 20,072 shs.
  • Short Ratio: 0.3
 

Frequently Asked Questions for NovaBay Pharmaceuticals (NYSE:NBY)

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "NBY."

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.01. The company had revenue of $4.12 million for the quarter, compared to analyst estimates of $4.57 million. NovaBay Pharmaceuticals had a negative return on equity of 184.30% and a negative net margin of 42.16%. View NovaBay Pharmaceuticals' Earnings History.

When will NovaBay Pharmaceuticals make its next earnings announcement?

NovaBay Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for NovaBay Pharmaceuticals.

Where is NovaBay Pharmaceuticals' stock going? Where will NovaBay Pharmaceuticals' stock price be in 2017?

5 brokers have issued 12 month price targets for NovaBay Pharmaceuticals' shares. Their predictions range from $6.00 to $10.00. On average, they anticipate NovaBay Pharmaceuticals' share price to reach $7.00 in the next year. View Analyst Ratings for NovaBay Pharmaceuticals.

What are analysts saying about NovaBay Pharmaceuticals stock?

Here are some recent quotes from research analysts about NovaBay Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. " (9/21/2017)
  • 2. Maxim Group analysts commented, "NovaBay reported 4Q16 revenue of 4M, inline with preannouncement back in January. Operating expenses were $6.1M up from the prior quarter's $5.5M. This translated into a net loss of $1.6M or $(0.11) per share. Novabay ended the quarter with $9.5M in cash or about $7M (est.) in cash today... We have adjusted our model to reflect the revenue guidance. We conclude that without a revenue breakout, (driven by additional capital), our model suggests a target valuation in the current range. As such, we maintain our Hold rating." (3/24/2017)

Who are some of NovaBay Pharmaceuticals' key competitors?

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the folowing people:

  • Mark M. Sieczkarek, Interim Chairman of the Board, President, Chief Executive Officer
  • John McGovern, Chief Financial Officer, Treasurer
  • Justin M. Hall Esq., Senior Vice President, General Counsel
  • Xinzhou Li, Director
  • Xiaoyan Liu, Director
  • Yonghao Ma Ph.D., Director
  • Mijia Wu, Director
  • Todd E. Zavodnick, Director

Who owns NovaBay Pharmaceuticals stock?

NovaBay Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.17%). View Institutional Ownership Trends for NovaBay Pharmaceuticals.

Who bought NovaBay Pharmaceuticals stock? Who is buying NovaBay Pharmaceuticals stock?

NovaBay Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for NovaBay Pharmaceuticals.

How do I buy NovaBay Pharmaceuticals stock?

Shares of NovaBay Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NovaBay Pharmaceuticals' stock price today?

One share of NovaBay Pharmaceuticals stock can currently be purchased for approximately $4.60.


MarketBeat Community Rating for NovaBay Pharmaceuticals (NYSE NBY)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  89
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NovaBay Pharmaceuticals (NYSE:NBY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $7.00 (52.17% upside)

Analysts' Ratings History for NovaBay Pharmaceuticals (NYSE:NBY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/20/2017Roth CapitalSet Price TargetBuy$6.00HighView Rating Details
8/11/2017Maxim GroupReiterated RatingHoldHighView Rating Details
8/11/2017HC WainwrightSet Price TargetBuy$6.00HighView Rating Details
3/27/2017LaidlawInitiated CoverageBuy -> Buy$10.00MediumView Rating Details
2/6/2017Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for NovaBay Pharmaceuticals (NYSE:NBY)
Earnings by Quarter for NovaBay Pharmaceuticals (NYSE:NBY)
Earnings History by Quarter for NovaBay Pharmaceuticals (NYSE NBY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.07)N/AView Earnings Details
8/10/2017Q2 2017($0.12)($0.11)$4.57 million$4.12 millionViewN/AView Earnings Details
11/10/2016Q316($0.16)($0.34)$3.02 million$3.40 millionViewN/AView Earnings Details
8/11/2016Q216($0.30)($0.36)$1.76 million$2.70 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NovaBay Pharmaceuticals (NYSE:NBY)
Current Year EPS Consensus Estimate: $-0.47 EPS
Next Year EPS Consensus Estimate: $-0.07 EPS

Dividends

Dividend History for NovaBay Pharmaceuticals (NYSE:NBY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for NovaBay Pharmaceuticals (NYSE:NBY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for NovaBay Pharmaceuticals (NYSE:NBY)
Latest Headlines for NovaBay Pharmaceuticals (NYSE:NBY)
Source:
DateHeadline
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - September 23 at 7:14 PM
finance.yahoo.com logoNovaBay Pharmaceuticals Receives Notification of Noncompliance with Additional NYSE American Continued Listing Standards
finance.yahoo.com - September 22 at 10:40 AM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 13 at 6:44 PM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Expected to Announce Quarterly Sales of $5.01 Million
www.americanbankingnews.com - September 9 at 5:12 PM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Expected to Announce Earnings of -$0.07 Per Share
www.americanbankingnews.com - September 7 at 4:26 AM
americanbankingnews.com logoHead-To-Head Comparison: NovaBay Pharmaceuticals (NBY) & Incyte Corporation (INCY)
www.americanbankingnews.com - September 5 at 12:17 PM
americanbankingnews.com logoRoth Capital Analysts Give NovaBay Pharmaceuticals, Inc. (NBY) a $6.00 Price Target
www.americanbankingnews.com - August 21 at 6:02 PM
americanbankingnews.com logo$5.08 Million in Sales Expected for NovaBay Pharmaceuticals, Inc. (NBY) This Quarter
www.americanbankingnews.com - August 21 at 4:44 AM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 19 at 4:48 PM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) PT Set at $6.00 by HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM
americanbankingnews.com logoNovaBay Pharmaceuticals' (NYSE:NBY) Hold Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - August 11 at 3:14 PM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Announces Earnings Results
www.americanbankingnews.com - August 11 at 12:38 PM
rttnews.com logoACHV Soars On New Achievement, AEZS Shrinks Q2 Loss, TXMD On Watch
www.rttnews.com - August 11 at 6:50 AM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NYSE:NBY) Downgraded by Zacks Investment Research
www.americanbankingnews.com - August 6 at 8:56 AM
americanbankingnews.com logo Analysts Anticipate NovaBay Pharmaceuticals, Inc. (NBY) Will Post Quarterly Sales of $4.57 Million
www.americanbankingnews.com - August 3 at 7:52 AM
businesswire.com logoRevance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics
www.businesswire.com - August 2 at 6:16 AM
americanbankingnews.com logo-$0.12 EPS Expected for NovaBay Pharmaceuticals, Inc. (NYSE:NBY) This Quarter
www.americanbankingnews.com - August 1 at 10:21 AM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NYSE:NBY) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 25 at 4:50 PM
finance.yahoo.com logoFighting Parasitic Eyelid Mites with Avenova from NovaBay Pharmaceuticals
finance.yahoo.com - July 25 at 5:51 AM
americanbankingnews.com logo$4.62 Million in Sales Expected for NovaBay Pharmaceuticals, Inc. (NBY) This Quarter
www.americanbankingnews.com - July 12 at 12:14 PM
americanbankingnews.com logo Analysts Expect NovaBay Pharmaceuticals, Inc. (NYSE:NBY) to Announce -$0.12 Earnings Per Share
www.americanbankingnews.com - July 10 at 8:08 AM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 30 at 11:15 AM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Given a $6.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - June 21 at 11:22 PM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Expected to Post Quarterly Sales of $4.57 Million
www.americanbankingnews.com - June 16 at 7:16 PM
americanbankingnews.com logoZacks: Brokerages Expect NovaBay Pharmaceuticals, Inc. (NBY) Will Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - June 14 at 8:34 AM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 5 at 11:28 AM
americanbankingnews.com logoRoth Capital Begins Coverage on NovaBay Pharmaceuticals, Inc. (NBY)
www.americanbankingnews.com - June 5 at 8:34 AM
finance.yahoo.com logoNovaBay Pharmaceuticals to Present at the 7th Annual LD Micro Invitational
finance.yahoo.com - May 30 at 6:52 AM
americanbankingnews.com logo NovaBay Pharmaceuticals, Inc. (NBY) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 26 at 2:30 PM
finance.yahoo.com logoTetraphase Pharmaceuticals, Inc. (TTPH)
finance.yahoo.com - May 19 at 11:31 AM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 18 at 11:34 PM
seekingalpha.com logoNovaBay Pharmaceuticals' (NBY) CEO Mark Sieczkarek on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 7:25 PM
finance.yahoo.com logoNovaBay Pharmaceuticals to Hold 2017 First Quarter Conference Call on May 11, 2017
finance.yahoo.com - May 4 at 11:27 AM
americanbankingnews.com logoZacks: NovaBay Pharmaceuticals, Inc. (NBY) Given $6.00 Average Price Target by Analysts
www.americanbankingnews.com - May 4 at 9:17 AM
americanbankingnews.com logoNovaBay Pharmaceuticals (NBY) Earns Media Sentiment Score of 0.44
www.americanbankingnews.com - May 3 at 12:20 AM
finance.yahoo.com logoAvenova from NovaBay Pharmaceuticals is Effective for Managing Dry Eye before Refractive and Cataract Eye Surgery
finance.yahoo.com - May 2 at 6:59 PM
americanbankingnews.com logoNovaBay Pharmaceuticals (NBY) Receives Daily Media Sentiment Score of -0.39
www.americanbankingnews.com - April 29 at 7:39 AM
americanbankingnews.com logoNovaBay Pharmaceuticals (NBY) Getting Somewhat Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 26 at 6:14 PM
americanbankingnews.com logoNovaBay Pharmaceuticals (NBY) Receiving Positive News Coverage, Study Finds
www.americanbankingnews.com - April 21 at 7:17 PM
americanbankingnews.com logo NovaBay Pharmaceuticals, Inc. (NBY) Given $6.00 Consensus Target Price by Analysts
www.americanbankingnews.com - April 17 at 6:37 PM
americanbankingnews.com logoNovaBay Pharmaceuticals (NBY) Getting Somewhat Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 17 at 3:58 PM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 15 at 8:42 AM
americanbankingnews.com logoNovaBay Pharmaceuticals' (NBY) Hold Rating Reiterated at Maxim Group
www.americanbankingnews.com - April 1 at 11:31 PM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Coverage Initiated by Analysts at Laidlaw
www.americanbankingnews.com - March 31 at 11:50 AM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Receives "Hold" Rating from Maxim Group
www.americanbankingnews.com - March 30 at 9:10 AM
americanbankingnews.com logoAnalysts Anticipate NovaBay Pharmaceuticals, Inc. (NBY) to Announce ($0.14) Earnings Per Share
www.americanbankingnews.com - March 29 at 12:20 PM
finance.yahoo.com logoAvenova from NovaBay Pharmaceuticals Effective for Painful Eye Condition
finance.yahoo.com - March 28 at 10:11 AM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Given a $6.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 27 at 2:49 PM
bloomberg.com logoU.S. Stocks Post Worst Week Since Election as Health Bill Fails
www.bloomberg.com - March 24 at 6:43 PM
finance.yahoo.com logoNovaBay Pharmaceuticals to Present at 29th Annual ROTH Conference
finance.yahoo.com - March 7 at 10:13 AM

Social

Chart

NovaBay Pharmaceuticals (NBY) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff